Table 2.
Patient treatment and outcomes
| Variable | Non-CVD (n 135) | CVD (n 33) |
|---|---|---|
| Pre-hospital treatment | ||
| Drug assisted intubation (%) | 47 (94%) | 17 (90%) |
| Hypertonic saline (NaCl 5%) n (%) | 40 (30%) | 13 (39%) |
| Blood products (PRBC) | 0 (0) | 0 (0–2) ** |
| Blood products (FFP) | 0 (0) | 0 (0–1) ** |
| 24 hour blood transfusion (units) | 0 (0) | 3 (0–8) ** |
| Neurosurgical intervention | 48 (43%) | 13 (43%) |
| ICU length of stay (days) | 11 (3–19) | 12 (2–25) |
| Vasopressor days | 2 (0–5) | 2 (0–4) |
| Total LOS (days) | 28 (13–47) | 32 (10–61) |
| Time to death (days) | 2.5 (2–6) | 2.5 (1–6) |
| 28-day mortality | 42 (31%) | 20 (61%) ** |
ICU, intensive care unit; LOS, length of stay. *Signifies P < 0.05 and **P <0.01 comparing CVD with non-CVD groups (Mann–Whitney U or chi-squared tests). Pre-hospital Intubation was only recorded in the LAA cohort; hence, it was not documented in n = 85 (non-CVD) and n = 14 (CVD) patients. Patients who had an intubation without drugs will not have been included.